< Back to Search

Neurology® Podcast - August 22 2017 Issue

Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome

Show description/summary: 1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome 2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows Progression This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurolog Read More

Download this Episode

Episode Segments

Interview: Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome (00:50 - 09:35)
00:50 09:35

Play Segment

Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome.

Neurology Today®: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows Progression (09:35 - 18:39)
09:35 18:39

Play Segment

Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS.

Top

FOR MORE INFORMATION

Email pbaskin@neurology.org

Footer